Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
ORGANIZATION
JGA Deeply Sorry for Making Baseless Demand on FY2016 Drug Pricing Reform
The Japan Generic Medicines Association (JGA) on December 25 apologized deeply for making a demand related to first generic pricing rules that later proved not to be based on actual market conditions. The JGA offered apologies in a statement issued…
To read the full story
Related Article
- Chuikyo OKs Outline of FY2016 Drug Pricing Reform
December 25, 2015
- Survey Finds Unexpectedly Low Market Prices for Injectable Generics; Industry to Accept 50% Rule
December 17, 2015
- Industry Opposes Expanded Price Cuts under Z2 Rule, Calls for Retention of 60% Pricing Rule for New Injectable, Topical Generics
December 10, 2015
ORGANIZATION
- Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
- Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
- Labor Federation Files Request for 5% Drug Price Hike with Health Minister
November 28, 2025
- Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…